MAT / RESEARCH / SPECIMENSPEC v3.2 · SPECIMEN

01 / STATEMENT

Matilon Research · Schema v3.2 · Record Specimen

Record Specimen

The following document is a complete specimen of a Matilon Research issuance, rendered across all three issued representations. Issuances distributed to authorized recipients adhere to this format and structure.

02 / REPRESENTATION

Representation

The same canonical record is rendered below in three issued representations: Issued Document (PDF/A-2b), HTML, and Structured Text.

Format: PDF/A-2b · Distributed to authorized recipients.

MT-2026-02-18-V1.htmltext/html; charset=UTF-8 · 144 LINES · 9.6 KB

<!DOCTYPE html>

<head>

</head>

<body>

<h1>MATILON RESEARCH</h1>

</header>

<h2>RECORD_CONTROL</h2>

<dl>

<dt>TYPE:</dt><dd>INTELLIGENCE RECORD</dd>

<dt>RECORD_ID:</dt><dd>MT-2026-02-18-V1</dd>

<dt>PRECEDING_RECORD:</dt><dd>MT-2026-02-11-V1</dd>

<dt>RECORD_SIGNATURE:</dt><dd>7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04</dd>

<dt>VERSION:</dt><dd>1.0</dd>

<dt>STATUS:</dt><dd>FINALIZED</dd>

<dt>ISSUED:</dt><dd>2026-02-18</dd>

<dt>RECORD_MODE:</dt><dd>APPEND-ONLY</dd>

<dt>RETENTION_PERIOD:</dt><dd>PERMANENT</dd>

<dt>SCHEMA_VERSION:</dt><dd>3.2</dd>

<dt>ACCESS_CLASSIFICATION:</dt><dd>EXECUTIVE</dd>

<dt>ENTRY_COUNT:</dt><dd>5</dd>

</dl>

</section>

<h2>CONFIDENTIALITY_NOTICE</h2>

<p>This document and all associated data, content, and information ("Material") are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient's organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.</p>

</section>

<h2>INTELLIGENCE_RECORD</h2>

<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E1</dd>

<dt>INGESTION_ID:</dt><dd>3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19</dd>

<dt>ENTITY:</dt><dd>FUJIFILM BIOTECHNOLOGIES</dd>

<dt>SUBJECT:</dt><dd>TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION</dd>

<dt>SUBJECT_CLASS:</dt><dd>EXPANSION</dd>

<dt>DOMAIN:</dt><dd>BIOMANUFACTURING CAPACITY</dd>

<dt>GEOGRAPHY:</dt><dd>UNITED KINGDOM</dd>

<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>

</dl>

<h3>DEFINITION:</h3>

<p>FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.</p>

<h3>STRUCTURE:</h3>

<p>End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.</p>

<h3>EFFECT:</h3>

<p>Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.</p>

</div>

</article>

<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E2</dd>

<dt>INGESTION_ID:</dt><dd>8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63</dd>

<dt>ENTITY:</dt><dd>MADE SCIENTIFIC; STREAMLINE BIO</dd>

<dt>SUBJECT:</dt><dd>ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION</dd>

<dt>SUBJECT_CLASS:</dt><dd>INTEGRATION</dd>

<dt>DOMAIN:</dt><dd>AUTOMATED CELL THERAPY SYSTEMS</dd>

<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>

<dt>FUNCTIONAL_DOMAIN:</dt><dd>ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>

</dl>

<h3>DEFINITION:</h3>

<p>Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.</p>

<h3>STRUCTURE:</h3>

<p>New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.</p>

<h3>EFFECT:</h3>

<p>Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.</p>

</div>

</article>

<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E3</dd>

<dt>INGESTION_ID:</dt><dd>1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47</dd>

<dt>ENTITY:</dt><dd>OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB</dd>

<dt>SUBJECT:</dt><dd>LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT</dd>

<dt>SUBJECT_CLASS:</dt><dd>SUPPLY</dd>

<dt>DOMAIN:</dt><dd>VIRAL VECTOR MANUFACTURING</dd>

<dt>GEOGRAPHY:</dt><dd>UNITED KINGDOM; UNITED STATES</dd>

<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS</dd>

</dl>

<h3>DEFINITION:</h3>

<p>Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.</p>

<h3>STRUCTURE:</h3>

<p>Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.</p>

<h3>EFFECT:</h3>

<p>Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.</p>

</div>

</article>

<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E4</dd>

<dt>INGESTION_ID:</dt><dd>5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72</dd>

<dt>ENTITY:</dt><dd>GEMINIBIO; TOLEMY BIO</dd>

100

<dt>SUBJECT:</dt><dd>AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION</dd>

101

<dt>SUBJECT_CLASS:</dt><dd>DEPLOYMENT</dd>

102

<dt>DOMAIN:</dt><dd>BIOPROCESS MEDIA DESIGN</dd>

103

<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>

104

<dt>FUNCTIONAL_DOMAIN:</dt><dd>PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS</dd>

105

</dl>

106

107

<h3>DEFINITION:</h3>

108

<p>GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.</p>

109

<h3>STRUCTURE:</h3>

110

<p>AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.</p>

111

<h3>EFFECT:</h3>

112

<p>Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.</p>

113

</div>

114

</article>

115

116

117

<dt>ENTRY_ID:</dt><dd>MT-2026-02-18-V1-E5</dd>

118

<dt>INGESTION_ID:</dt><dd>9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94</dd>

119

<dt>ENTITY:</dt><dd>NUCLEUS BIOLOGICS</dd>

120

<dt>SUBJECT:</dt><dd>KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH</dd>

121

<dt>SUBJECT_CLASS:</dt><dd>DEPLOYMENT</dd>

122

<dt>DOMAIN:</dt><dd>POINT-OF-USE MEDIA SYSTEMS</dd>

123

<dt>GEOGRAPHY:</dt><dd>UNITED STATES</dd>

124

<dt>FUNCTIONAL_DOMAIN:</dt><dd>AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING</dd>

125

</dl>

126

127

<h3>DEFINITION:</h3>

128

<p>Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.</p>

129

<h3>STRUCTURE:</h3>

130

<p>QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.</p>

131

<h3>EFFECT:</h3>

132

<p>Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.</p>

133

</div>

134

</article>

135

</section>

136

137

<h2>DISCLAIMER_OF_LIABILITY</h2>

138

<p>This document and all associated data, content, analyses, and information ("Material") are provided by Matilon for informational and internal decision-support purposes only. The Material is provided without representation as to its completeness or sufficiency; accordingly, Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient's sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material and reserves all rights with respect to its use and distribution.</p>

139

</section>

140

141

<p>MT-2026-02-18-V1 · V1.0 · 2026-02-18 · © MATILON · CONFIDENTIAL</p>

142

</footer>

143

</body>

144

</html>

MT-2026-02-18-V1.txttext/plain; charset=UTF-8 · 118 LINES · 6.8 KB

MATILON RESEARCH

RECORD_CONTROL

TYPE: INTELLIGENCE RECORD

RECORD_ID: MT-2026-02-18-V1

PRECEDING_RECORD: MT-2026-02-11-V1

RECORD_SIGNATURE: 7A2E9C4F-3B81-4D56-A9E3-2F7C8B1D5E04

VERSION: 1.0

STATUS: FINALIZED

ISSUED: 2026-02-18

RECORD_MODE: APPEND-ONLY

RETENTION_PERIOD: PERMANENT

SCHEMA_VERSION: 3.2

ACCESS_CLASSIFICATION: EXECUTIVE

ENTRY_COUNT: 5

CONFIDENTIALITY_NOTICE

This document and all associated data, content, and information ("Material") are proprietary to Matilon and are provided solely for authorized use. The Material may contain confidential, sensitive, or privileged information. Unauthorized access, use, disclosure, distribution, reproduction, or retention of any portion of the Material is strictly prohibited. Recipients shall protect the Material with reasonable care and use it solely for its intended purpose. The Material may not be shared, disclosed, or made accessible, in whole or in part, outside the recipient's organization without prior written authorization from Matilon. Recipients shall ensure that any permitted access to the Material is limited to authorized personnel under equivalent confidentiality obligations.

INTELLIGENCE_RECORD

ENTRY_ID: MT-2026-02-18-V1-E1

INGESTION_ID: 3C9F1A47-5D8B-4E62-B1F4-8A2E6C5D3B19

ENTITY: FUJIFILM BIOTECHNOLOGIES

SUBJECT: TEESSIDE SINGLE-USE BIOREACTOR CAPACITY EXPANSION

SUBJECT_CLASS: EXPANSION

DOMAIN: BIOMANUFACTURING CAPACITY

GEOGRAPHY: UNITED KINGDOM

FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS

DEFINITION:

FUJIFILM Biotechnologies opened a £400 million Teesside expansion, adding 2,000 L and 5,000 L single-use bioreactors alongside new process development laboratories.

STRUCTURE:

End-to-end workflows now run from customer-supplied DNA through cell line development to 5,000 L scale-up, reducing external handoffs during tech transfer.

EFFECT:

Raises the value of standardized process definitions, facility layouts, and shared digital templates as Teesside aligns with FUJIFILM's Toyama facility.

ENTRY_ID: MT-2026-02-18-V1-E2

INGESTION_ID: 8E4A2F91-6C3D-4B57-9A2E-1F5C8D7B4A63

ENTITY: MADE SCIENTIFIC; STREAMLINE BIO

SUBJECT: ROBOTIC CAR-T PLATFORM INTEGRATION AND VALIDATION

SUBJECT_CLASS: INTEGRATION

DOMAIN: AUTOMATED CELL THERAPY SYSTEMS

GEOGRAPHY: UNITED STATES

FUNCTIONAL_DOMAIN: ADVANCED THERAPIES MANUFACTURING; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS

DEFINITION:

Made Scientific joined Streamline Bio's early adopter program to integrate and validate Streamline's AI-driven robotic platform within Made's GMP operations.

STRUCTURE:

New unit operations, enhanced in-process analytics, and expanded data capture characterize autonomous CAR-T steps across cycle time, robustness, and scalability.

EFFECT:

Concentrates early validation and integration patterns at a single CDMO site, accelerating later rollout while deepening dependence on site-specific procedures.

ENTRY_ID: MT-2026-02-18-V1-E3

INGESTION_ID: 1D6B3E84-7F92-4A58-B3C1-5E2F9A8D6C47

ENTITY: OXFORD BIOMEDICA; BRISTOL MYERS SQUIBB

SUBJECT: LENTIVIRAL VECTOR COMMERCIAL SUPPLY AGREEMENT

SUBJECT_CLASS: SUPPLY

DOMAIN: VIRAL VECTOR MANUFACTURING

GEOGRAPHY: UNITED KINGDOM; UNITED STATES

FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; TECH TRANSFER AND CMC PROGRAM LEADERSHIP; EXECUTIVE MANUFACTURING AND TECHOPS

DEFINITION:

Oxford Biomedica signed a five-year commercial supply agreement, with an extension option, to manufacture lentiviral vectors for Bristol Myers Squibb CAR-T programs.

STRUCTURE:

Commercial manufacturing is expected to begin in 2026, subject to regulatory approvals, across Oxford, United Kingdom and Durham, North Carolina sites.

EFFECT:

Requires aligned control strategies, harmonized release specifications, and quality data exchange across both sites to hold consistent commercial output through the supply term.

ENTRY_ID: MT-2026-02-18-V1-E4

INGESTION_ID: 5F2C9A18-3E7B-4D64-A8F2-6B1E5C9D3A72

ENTITY: GEMINIBIO; TOLEMY BIO

SUBJECT: AI-DRIVEN CUSTOM MEDIA SUPPLEMENT SERVICE INTRODUCTION

SUBJECT_CLASS: DEPLOYMENT

DOMAIN: BIOPROCESS MEDIA DESIGN

GEOGRAPHY: UNITED STATES

FUNCTIONAL_DOMAIN: PROCESS DEVELOPMENT AND MSAT; AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS

DEFINITION:

GeminiBio and Tolemy Bio introduced aiMOS, a service applying AI/ML and multi-omics to design custom media supplements for cell therapy processes and manufacture them to cGMP standards.

STRUCTURE:

AI/ML modeling over multi-omics data designs custom supplements for tighter critical quality attributes and lower batch variability, reducing iterative media tuning cycles.

EFFECT:

Adds dataset governance and supplement change-control requirements, with model outputs needing controlled mapping into MES, CMC documentation, and release records before formulations reach GMP production.

ENTRY_ID: MT-2026-02-18-V1-E5

INGESTION_ID: 9A7E4C2F-8B5D-4163-9E2A-3F8C1B6D5E94

ENTITY: NUCLEUS BIOLOGICS

SUBJECT: KRAKATOA K500 POINT-OF-USE MEDIA POD LAUNCH

SUBJECT_CLASS: DEPLOYMENT

DOMAIN: POINT-OF-USE MEDIA SYSTEMS

GEOGRAPHY: UNITED STATES

FUNCTIONAL_DOMAIN: AUTOMATION AND DIGITAL MANUFACTURING SYSTEMS; ADVANCED THERAPIES MANUFACTURING

DEFINITION:

Nucleus Biologics launched Krakatoa K500, a pod-based single-use system producing 35–500 L of sterile media and buffers at the point of use.

STRUCTURE:

QR-code execution, inline pH and conductivity monitoring, and automated digital batch records reduce centralized liquid prep and cold storage while preserving traceability.

EFFECT:

Shifts media and buffer preparation to the point of use, reopening qualification boundaries, cleanroom layouts, and validation scope as liquid prep moves beside the bioreactor.

DISCLAIMER_OF_LIABILITY

This document and all associated data, content, analyses, and information ("Material") are provided by Matilon for informational and internal decision-support purposes only. The Material is provided without representation as to its completeness or sufficiency; accordingly, Matilon makes no representations or warranties, express or implied, as to the accuracy, completeness, timeliness, reliability, or fitness for any particular purpose of the Material. The Material does not constitute legal, financial, technical, or strategic advice, and shall not be relied upon as the sole basis for any decision, action, or omission. Any use of or reliance on the Material is undertaken at the recipient's sole risk and discretion. To the fullest extent permitted by applicable law, Matilon disclaims all liability for any direct, indirect, incidental, consequential, or special damages arising out of or in connection with the use of, or inability to use, the Material, including any errors or omissions therein. Matilon assumes no obligation to update, correct, revise, or supplement the Material and reserves all rights with respect to its use and distribution.

03 / CROSS-REFERENCES

Cross-References

Record Index

Schema Reference

Extraction Specification

Matilon Research Specimen · Schema v3.2